Cargando…

Outcomes Comparing Initial Short vs Long Course Echinocandin Therapy in Patients with Candidemia Caused by Fluconazole Susceptible Strains

BACKGROUND: Guidelines for candidemia (CAND) treatment recommend initial echinocandin (ECHINO) therapy with transition to fluconazole (FLUC) after 5–7 days in patients with clinical stability, FLUC-susceptibility, and negative cultures; however, optimal timing for transition is unknown. In the era o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Small-Saunders, Jennifer L, Loo, Angela, Theodore, Deborah, Singh, Amrita, Sobieszczyk, Magdalena, Kubin, Christine J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631745/ http://dx.doi.org/10.1093/ofid/ofx163.023

Ejemplares similares

2117. Fluconazole vs. Echinocandins as Initial Therapy for Candidemia Caused by Fluconazole-Susceptible Species in the Era of Rapid Diagnostic Testing
por: Roshdy, Danya, et al.
Publicado: (2019)

The Effect on Mortality of Fluconazole or Echinocandins Treatment in Candidemia in Internal Medicine Wards
por: De Rosa, Francesco G., et al.
Publicado: (2015)

Correction: The Effect on Mortality of Fluconazole or Echinocandins Treatment in Candidemia in Internal Medicine Wards
Publicado: (2015)

Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients
por: Grau, S, et al.
Publicado: (2015)

Evaluation of Fluconazole versus Echinocandins for Treatment of Candidemia Caused by Susceptible Common Candida Species: A Propensity Score Matching Analysis
por: Kim, Jong Hun, et al.
Publicado: (2023)

Early Stepdown From Echinocandin to Fluconazole Treatment in Candidemia: A Post Hoc Analysis of Three Cohort Studies
por: Moreno-García, E, et al.
Publicado: (2021)

Decreased echinocandin susceptibility in Candida parapsilosis causing candidemia and emergence of a pan-echinocandin resistant case in China
por: Ning, Yating, et al.
Publicado: (2022)

Correction to: Early Stepdown From Echinocandin to Fluconazole Treatment in Candidemia: A Post Hoc Analysis of Three Cohort Studies
por: Moreno-García, E, et al.
Publicado: (2022)

146 Review of Empiric Echinocandin Therapy for Candidemia
por: Amado, Cristina, et al.
Publicado: (2014)

372. Attributable Mortality of Candidemia After Introduction of Echinocandins
por: Cornely, Florian, et al.
Publicado: (2018)

Determinants of fluconazole resistance and echinocandin tolerance in C. parapsilosis isolates causing a large clonal candidemia outbreak among COVID-19 patients in a Brazilian ICU
por: Daneshnia, Farnaz, et al.
Publicado: (2022)

Impact of echinocandins as first-choice therapy in cardiothoracic high-risk patients with candidemia
por: Langebartels, G, et al.
Publicado: (2013)

Treatment of candidemia in a nationwide setting: increased survival with primary echinocandin treatment
por: Lausch, Karen Rokkedal, et al.
Publicado: (2018)

Factors associated with the development of ocular candidiasis and ocular prognosis with echinocandin therapy for candidemia
por: Sakai, Daiki, et al.
Publicado: (2021)

Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007
por: Poikonen, Eira, et al.
Publicado: (2010)

Impact of the Disk Diffusion Test on Fluconazole De-Escalation in Patients with Candidemia
por: Tantasuwan, Suchavadee, et al.
Publicado: (2022)

Antifungal drug susceptibility, molecular basis of resistance to echinocandins and molecular epidemiology of fluconazole resistance among clinical Candida glabrata isolates in Kuwait
por: Al-Baqsami, Zahraa F., et al.
Publicado: (2020)

The In Vitro Activity of Fluconazole, Amphotericin B and Echinocandins Against Cyberlindnera fabianii Planktonic Cells and Biofilms
por: Tóth, Zoltán, et al.
Publicado: (2022)

Recurrent episodes of Candidemia due to Candida glabrata, Candida tropicalis and Candida albicans with acquired echinocandin resistance
por: Grosset, Marine, et al.
Publicado: (2016)

Evaluation of the early fluconazole treatment of candidemia protocol with automated short message service alerts: a before-and-after study
por: Yoo, Jeong Rae, et al.
Publicado: (2021)

Development of High-Level Echinocandin Resistance in a Patient With Recurrent Candida auris Candidemia Secondary to Chronic Candiduria
por: Biagi, Mark J, et al.
Publicado: (2019)

Outbreak of candidemia caused by fluconazole resistant Candida parapsilosis strains in an intensive care unit
por: Pinhati, Henrique Marconi Sampaio, et al.
Publicado: (2016)

Epidemiology of Candidemia and Fluconazole Resistance in an ICU before and during the COVID-19 Pandemic Era
por: Routsi, Christina, et al.
Publicado: (2022)

Cost-utility analysis of caspofungin and fluconazole for primary treatment of invasive candidiasis and candidemia in Ethiopia
por: Gebretekle, Gebremedhin Beedemariam, et al.
Publicado: (2022)

The in vitro Activity of Echinocandins Against Clinical Trichophyton rubrum Isolates and Review of the Susceptibility of T. rubrum to Echinocandins Worldwide
por: Su, Huilin, et al.
Publicado: (2023)

Fatal Breakthrough Candidemia in an Immunocompromised Patient in Kuwait Due to Candida auris Exhibiting Reduced Susceptibility to Echinocandins and Carrying a Novel Mutation in Hotspot-1 of FKS1
por: Al-Obaid, Inaam, et al.
Publicado: (2022)

Incidence of candidemia before and after fluconazole prophylaxis implementation in a 14-bed general ICU
por: Vartzeli, P, et al.
Publicado: (2008)

468. Assessment of The Proportion of Hospitalized Patients (Pts) with Candidemia (C) and Invasive Candidiasis without Candidemia (IC) Who Received an Echinocandin (EC) and Were Potentially Eligible for an Earlier Hospital Discharge (HD)
por: Lodise, Thomas, et al.
Publicado: (2022)

2116. Comparative Effectiveness of Amphotericin B, Azoles, and Echinocandins in the Treatment of Candidemia and Invasive Candidiasis: A Systematic Review and Network Meta-Analysis
por: Demir, Koray K, et al.
Publicado: (2019)

The impact of caspase-12 on susceptibility to candidemia
por: Rosentul, D. C., et al.
Publicado: (2011)

The Epidemiology and Susceptibility of Candidemia in Jerusalem, Israel
por: Israel, Sarah, et al.
Publicado: (2019)

Fluconazole and echinocandin resistance of Candida species in invasive candidiasis at a university hospital during pre-COVID-19 and the COVID-19 outbreak
por: Szekely, Jidapa, et al.
Publicado: (2023)

Draft Genome Sequence of a Fluconazole-Resistant Candida auris Strain from a Candidemia Patient in India
por: Sharma, Cheshta, et al.
Publicado: (2015)

A Brazilian Inter-Hospital Candidemia Outbreak Caused by Fluconazole-Resistant Candida parapsilosis in the COVID-19 Era
por: Thomaz, Danilo Y., et al.
Publicado: (2022)

Impact of the COVID-19 Pandemic on the Clinical Profile of Candidemia and the Incidence of Fungemia Due to Fluconazole-Resistant Candida parapsilosis
por: Ramos-Martínez, Antonio, et al.
Publicado: (2022)

Echinocandin-resistant Candida tropicalis Bloodstream Infections
por: Sfeir, Maroun, et al.
Publicado: (2017)

Rezafungin—Mechanisms of Action, Susceptibility and Resistance: Similarities and Differences with the Other Echinocandins
por: Garcia-Effron, Guillermo
Publicado: (2020)

No Impact of Fluconazole to Echinocandins Replacement as First-Line Therapy on the Epidemiology of Yeast Fungemia (Hospital-Driven Active Surveillance, 2004–2017, Paris, France)
por: Bretagne, Stéphane, et al.
Publicado: (2021)

Comparison of echinocandin antifungals
por: Eschenauer, Gregory, et al.
Publicado: (2007)

Fungal echinocandin resistance
por: Walker, Louise A., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_jt5v6feg26p5fpvf27mavu7hun